Upadacitinib,Adalimumab
Abbvie
['adalimumab', 'upadacitinib']
over a 3-year period, patients treated with #upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab. #eular2023
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.